Education
About Us
Working with TipRanks
Follow Us
NATCO Pharma Limited (IN:NATCOPHARM)
:NATCOPHARM
Total Valuation
NATCO Pharma Limited has a market cap or net worth of ₹146.90B. The enterprise value is ₹236.19B.
Market Cap₹146.90B
Enterprise Value₹236.19B
Share Statistics
NATCO Pharma Limited has 179,109,860 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding179,109,860
Owned by Insiders―
Owned by Institutions0.06%
Financial Efficiency
NATCO Pharma Limited’s return on equity (ROE) is 0.25 and return on invested capital (ROIC) is 30.97%.
Return on Equity (ROE)0.25
Return on Assets (ROA)0.22
Return on Invested Capital (ROIC)30.97%
Return on Capital Employed (ROCE)0.39
Revenue Per Employee11.04M
Profits Per Employee4.69M
Employee Count4,016
Asset Turnover0.51
Inventory Turnover0.95
Valuation Ratios
The current PE Ratio of NATCO Pharma Limited is 8.7. NATCO Pharma Limited’s PEG ratio is 0.21.
PE Ratio8.7
PS Ratio3.25
PB Ratio1.90
Price to Fair Value1.90
Price to FCF10.10
Price to Operating Cash Flow0.00
PEG Ratio0.21
Income Statement
In the last 12 months, NATCO Pharma Limited had revenue of 44.32B and earned 18.85B in profits. Earnings per share was 105.26.
Revenue44.32B
Gross Profit37.05B
Operating Income30.00B
Pretax Income22.91B
Net Income18.85B
EBITDA21.44B
Earnings Per Share (EPS)105.26
Cash Flow
In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.
Operating Cash Flow0.00
Free Cash Flow0.00
Free Cash Flow per Share0.00
Dividends & Yields
NATCO Pharma Limited pays an annual dividend of ₹1.5, resulting in a dividend yield of 0.62%
Dividend Per Share₹1.5
Dividend Yield0.62%
Payout Ratio7.53%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.12
52-Week Price Change-37.92%
50-Day Moving Average828.99
200-Day Moving Average875.29
Relative Strength Index (RSI)51.68
Average Volume (3m)59.22K
Important Dates
NATCO Pharma Limited upcoming earnings date is Feb 18, 2026, TBA (Confirmed).
Last Earnings DateNov 14, 2025
Next Earnings DateFeb 18, 2026
Ex-Dividend DateNov 20, 2025
Financial Position
NATCO Pharma Limited as a current ratio of 5.59, with Debt / Equity ratio of 0.00%
Current Ratio5.59
Quick Ratio4.77
Debt to Market Cap0.02
Net Debt to EBITDA-0.88
Interest Coverage Ratio163.95
Taxes
In the past 12 months, NATCO Pharma Limited has paid 4.08B in taxes.
Income Tax4.08B
Effective Tax Rate0.18
Enterprise Valuation
NATCO Pharma Limited EV to EBITDA ratio is 5.84, with an EV/FCF ratio of 8.77.
EV to Sales2.83
EV to EBITDA5.84
EV to Free Cash Flow8.77
EV to Operating Cash Flow7.38
Balance Sheet
NATCO Pharma Limited has ₹24.97B in cash and marketable securities with ₹0.00 in debt, giving a net cash position of ₹24.97B billion.
Cash & Marketable Securities₹24.97B
Total Debt₹0.00
Net Cash₹24.97B
Net Cash Per Share₹139.40
Tangible Book Value Per Share₹410.13
Margins
Gross margin is 82.26%, with operating margin of 67.70%, and net profit margin of 42.54%.
Gross Margin82.26%
Operating Margin67.70%
Pretax Margin51.70%
Net Profit Margin42.54%
EBITDA Margin48.38%
EBIT Margin44.36%
Analyst Forecast
The average price target for NATCO Pharma Limited is ―, which is 11.43% higher than the current price. The consensus rating is Moderate Sell
Price Target―
Price Target Upside―
Analyst ConsensusModerate Sell
Analyst Count0
Revenue Growth Forecast-3.79%
EPS Growth Forecast-20.88%